ArticleEuropean journal of nuclear medicine and molecular imaging2019
Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma.
Article in European journal of nuclear medicine and molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic Factors for Survival in Adults With Burkitt Lymphoma: A Systematic Review.Cancer medicine · 2025Pooled it
- High total metabolic tumor volume at baseline predicts survival independent of response to therapy.Blood · 2020Trial
- Dynamic Metabolic Parameters and Deauville Score on 18F-FDG PET/CT for Prognostic Assessment in Pediatric Burkitt Lymphoma.Children (Basel, Switzerland) · 2026Article
- Complementary prognostic value of hotspot-to-centroid distance (NHOCpeak) to SUVpeak in high-grade glioma.Annals of nuclear medicine · 2026Article
- Article
- An interpretable machine learning model for predicting bone marrow invasion in patients with lymphoma viaBMC medical informatics and decision making · 2025Article
- 2-[Annals of hematology · 2024Article
- Evaluation of therapeutic effect and prognostic value ofEJNMMI research · 2024Article
- The role ofQuantitative imaging in medicine and surgery · 2024Article
- 2-[Medicina (Kaunas, Lithuania) · 2024Article
- Radiomics predictive modeling from dual-time-point FDG PET KEJNMMI research · 2023Article
- Imaging recommendations in pediatric lymphoma: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper.Pediatric blood & cancer · 2023Article
- Development and validation of a [European radiology · 2023Article
- Diagnosis and prognostic predictive value of delineation methods fromAmerican journal of nuclear medicine and molecular imaging · 2023Article
- Prospective Evaluation of Different Methods for Volumetric Analysis on [Journal of clinical medicine · 2022Article
- Longitudinal Body Composition Changes Detected by [Cancers · 2022Article
- Prognostic value of pre-transplantation total metabolic tumor volume onInternational journal of hematology · 2022Article
- Primary intestinal Burkitt's lymphoma in a Syrian child with a challenging initial presentation: A case report and literature review.Annals of medicine and surgery (2012) · 2022Article
- Clinical Perspectives forMetabolites · 2022Review
- The optimal use of PET/CT in the management of lymphoma patients.The British journal of radiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBurkitt's lymphoma (BL) is an aggressive lymphoma subtype with high 18F-FDG avidity at 18F-FDG-PET/CT, but no validated criteria for PET/CT in treatment evaluation or prediction of outcome in BL are available. The aim of our study was to investigate whether the metabolic baseline PET/CT parameters can predict treatment response and prognosis in BL. MATERIALS AND
methodsWe retrospectively enrolled 65 patients who underwent baseline 18F-FDG-PET/CT, interim and end of treatment PET/CT. The PET images were analyzed visually and semi-quantitatively by measuring the maximum standardized uptake value body weight (SUVbw), the maximum standardized uptake value lean body mass (SUVlbm), the maximum standardized uptake value body surface area (SUVbsa), lesion to liver SUVmax ratio (L-L SUV R), lesion to blood-pool SUVmax ratio (L-BP SUV R), total metabolic tumor volume (tMTV) and total lesion glycolysis (TLG). Survival curves were plotted according to the Kaplan-Meier method.
resultsAt a median follow-up of 40 months, the median PFS and OS were 34 and 39 months. MTV and TLG were significantly higher in patients with partial response compared to complete response group at end of treatment, while no significant differences were found at interim. Other metabolic PET/CT parameters were not related to treatment response. MTV and TLG were demonstrated to be independent prognostic factors for both PFS and OS; instead SUVbw, SUVlbm, SUVbsa, L-L SUV R and L-BP SUV R were not related to outcome survival.
conclusionsMetabolic tumour features (MTV and TLG) were significantly correlated with response to treatment and long-term outcome.
Indexed as
Identifiers
30276438What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.